QQQ   359.75 (+1.36%)
AAPL   173.66 (+0.73%)
MSFT   318.96 (+1.77%)
META   305.58 (+1.54%)
GOOGL   135.24 (+2.12%)
AMZN   127.00 (+1.83%)
TSLA   261.16 (+5.93%)
NVDA   440.41 (+1.20%)
NIO   8.83 (+2.56%)
BABA   84.05 (-0.58%)
AMD   104.07 (+3.99%)
T   14.65 (-0.88%)
F   11.98 (-0.75%)
MU   68.11 (+0.41%)
CGC   0.75 (+10.25%)
GE   108.85 (+1.01%)
DIS   79.30 (-0.30%)
AMC   8.34 (+6.24%)
PFE   33.29 (-1.80%)
PYPL   58.57 (+2.22%)
NFLX   376.90 (+0.04%)
QQQ   359.75 (+1.36%)
AAPL   173.66 (+0.73%)
MSFT   318.96 (+1.77%)
META   305.58 (+1.54%)
GOOGL   135.24 (+2.12%)
AMZN   127.00 (+1.83%)
TSLA   261.16 (+5.93%)
NVDA   440.41 (+1.20%)
NIO   8.83 (+2.56%)
BABA   84.05 (-0.58%)
AMD   104.07 (+3.99%)
T   14.65 (-0.88%)
F   11.98 (-0.75%)
MU   68.11 (+0.41%)
CGC   0.75 (+10.25%)
GE   108.85 (+1.01%)
DIS   79.30 (-0.30%)
AMC   8.34 (+6.24%)
PFE   33.29 (-1.80%)
PYPL   58.57 (+2.22%)
NFLX   376.90 (+0.04%)
QQQ   359.75 (+1.36%)
AAPL   173.66 (+0.73%)
MSFT   318.96 (+1.77%)
META   305.58 (+1.54%)
GOOGL   135.24 (+2.12%)
AMZN   127.00 (+1.83%)
TSLA   261.16 (+5.93%)
NVDA   440.41 (+1.20%)
NIO   8.83 (+2.56%)
BABA   84.05 (-0.58%)
AMD   104.07 (+3.99%)
T   14.65 (-0.88%)
F   11.98 (-0.75%)
MU   68.11 (+0.41%)
CGC   0.75 (+10.25%)
GE   108.85 (+1.01%)
DIS   79.30 (-0.30%)
AMC   8.34 (+6.24%)
PFE   33.29 (-1.80%)
PYPL   58.57 (+2.22%)
NFLX   376.90 (+0.04%)
QQQ   359.75 (+1.36%)
AAPL   173.66 (+0.73%)
MSFT   318.96 (+1.77%)
META   305.58 (+1.54%)
GOOGL   135.24 (+2.12%)
AMZN   127.00 (+1.83%)
TSLA   261.16 (+5.93%)
NVDA   440.41 (+1.20%)
NIO   8.83 (+2.56%)
BABA   84.05 (-0.58%)
AMD   104.07 (+3.99%)
T   14.65 (-0.88%)
F   11.98 (-0.75%)
MU   68.11 (+0.41%)
CGC   0.75 (+10.25%)
GE   108.85 (+1.01%)
DIS   79.30 (-0.30%)
AMC   8.34 (+6.24%)
PFE   33.29 (-1.80%)
PYPL   58.57 (+2.22%)
NFLX   376.90 (+0.04%)
NASDAQ:CMMB

Chemomab Therapeutics (CMMB) Competitors

$0.88
-0.02 (-2.22%)
(As of 10/4/2023 ET)
Compare
Today's Range
$0.85
$0.89
50-Day Range
$0.88
$1.30
52-Week Range
$0.83
$5.35
Volume
19,327 shs
Average Volume
353,747 shs
Market Capitalization
$9.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

CMMB vs. BCEL, GTBP, TMBR, ARAV, LSDI, ATHE, CMRA, IMNN, GHSI, and APGN

Should you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Atreca (BCEL), GT Biopharma (GTBP), Timber Pharmaceuticals (TMBR), Aravive (ARAV), Lucy Scientific Discovery (LSDI), Alterity Therapeutics (ATHE), Comera Life Sciences (CMRA), Imunon (IMNN), Guardion Health Sciences (GHSI), and Apexigen (APGN). These companies are all part of the "pharmaceutical preparations" industry.

Chemomab Therapeutics vs.

Chemomab Therapeutics (NASDAQ:CMMB) and Atreca (NASDAQ:BCEL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

23.0% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 34.9% of Atreca shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 11.3% of Atreca shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Atreca received 85 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. Likewise, 67.86% of users gave Atreca an outperform vote while only 50.00% of users gave Chemomab Therapeutics an outperform vote.

CompanyUnderperformOutperform
Chemomab TherapeuticsOutperform Votes
10
50.00%
Underperform Votes
10
50.00%
AtrecaOutperform Votes
95
67.86%
Underperform Votes
45
32.14%

Chemomab Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Atreca has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.

Chemomab Therapeutics' return on equity of -101.15% beat Atreca's return on equity.

Company Net Margins Return on Equity Return on Assets
Chemomab TherapeuticsN/A -101.15% -84.19%
Atreca N/A -120.73%-58.69%

In the previous week, Chemomab Therapeutics and Chemomab Therapeutics both had 1 articles in the media. Chemomab Therapeutics' average media sentiment score of 1.37 beat Atreca's score of 0.00 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Chemomab Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Atreca
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chemomab TherapeuticsN/AN/A-$27.65M-$2.94-0.30
AtrecaN/AN/A-$97.16M-$2.18-0.12

Chemomab Therapeutics presently has a consensus price target of $7.00, indicating a potential upside of 695.64%. Atreca has a consensus price target of $10.75, indicating a potential upside of 4,125.63%. Given Atreca's stronger consensus rating and higher probable upside, analysts clearly believe Atreca is more favorable than Chemomab Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chemomab Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Atreca
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20

Summary

Atreca beats Chemomab Therapeutics on 10 of the 14 factors compared between the two stocks.


Get Chemomab Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMMB vs. The Competition

MetricChemomab TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$9.72M$5.38B$4.31B$6.31B
Dividend YieldN/A2.63%2.42%7.92%
P/E Ratio-0.306.91145.1413.01
Price / SalesN/A140.242,892.5651.72
Price / CashN/A22.5690.96105.64
Price / Book0.283.933.784.52
Net Income-$27.65M$156.14M$122.13M$182.18M
7 Day Performance-3.32%-3.61%-2.65%-2.12%
1 Month Performance-22.82%-12.51%-8.72%-9.25%
1 Year Performance-64.09%1.10%4.38%-0.86%

Chemomab Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCEL
Atreca
1.9083 of 5 stars
$0.26
-7.1%
$10.75
+4,034.6%
-86.3%$10.22MN/A-0.1290Gap Up
GTBP
GT Biopharma
2.0247 of 5 stars
$0.26
+4.1%
$3.50
+1,272.5%
-87.2%$10.36MN/A-0.552Positive News
Gap Down
TMBR
Timber Pharmaceuticals
0 of 5 stars
$3.03
+1.3%
$11.00
+263.0%
-38.7%$10.39M$80,000.000.009
ARAV
Aravive
2.1041 of 5 stars
$0.14
+7.8%
$10.17
+7,277.8%
-83.8%$10.14M$9.14M-0.0823Gap Up
High Trading Volume
LSDI
Lucy Scientific Discovery
0 of 5 stars
$0.62
-7.5%
N/AN/A$10.10MN/A0.00N/APositive News
Gap Up
ATHE
Alterity Therapeutics
1.9321 of 5 stars
$2.51
-4.6%
$10.00
+298.4%
-50.3%$10.07M$3.37M0.0011Gap Down
CMRA
Comera Life Sciences
0 of 5 stars
$0.39
+18.2%
N/A-84.2%$10.60M$1.10M-0.6612Gap Up
High Trading Volume
IMNN
Imunon
2.3639 of 5 stars
$1.04
+1.0%
$13.50
+1,200.3%
-38.7%$9.73M$250,000.00-0.2831
GHSI
Guardion Health Sciences
0 of 5 stars
$7.60
-0.3%
N/A+1.4%$9.65M$11.05M0.0012Short Interest ↑
APGN
Apexigen
0 of 5 stars
$0.39
flat
$11.50
+2,887.0%
N/A$9.57MN/A0.0011

Related Companies and Tools

This page (NASDAQ:CMMB) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -